|
TNFRSF10A
|
Neoplasms
|
0.400 |
AlteredExpression |
BEFREE |
Taken together, our study reveals that TRAIL-R1 through regulation of miR-370 can decrease the sensitivity of PDAC cells to TGFβ and therefore represents a potential tumour suppressor in late-stage PDAC.
|
30366420 |
2018 |
|
TNFRSF10A
|
Neoplasms
|
0.400 |
AlteredExpression |
BEFREE |
TRAIL-R1, TRAIL-R2 elevated relative mRNA levels inversely correlated with tumor stage (p = .036, p = .048).
|
29731264 |
2018 |
|
TNFRSF10A
|
Neoplasms
|
0.400 |
AlteredExpression |
BEFREE |
However, Kaplan-Meier analyses revealed significantly prolonged median survival of patients with positive cytoplasmic TRAIL-R1 expression in more than 80% of tumor cells compared to patients with tumors containing a smaller quantity of cells positively stained for cytoplasmic TRAIL-R1 (20 vs. 8 months; p = 0.004).
|
30064384 |
2018 |
|
TNFRSF10A
|
Neoplasms
|
0.400 |
Biomarker |
BEFREE |
However, TRAIL-R1/R2-based tumor therapy has not yet been realized.
|
28900492 |
2017 |
|
TNFRSF10A
|
Neoplasms
|
0.400 |
GeneticVariation |
BEFREE |
Furthermore, a significantly increased risk of high Gleason grade tumor was found in the combined variant allele carrier (GA + AA) of DR4 141 compared with the GG genotype (OR = 2.27, Pc = 0.052).
|
25691252 |
2015 |
|
TNFRSF10A
|
Neoplasms
|
0.400 |
Biomarker |
BEFREE |
Death receptor 4 (DR4) gene is a candidate tumor suppressor gene that has a role in apoptotic pathway.
|
23661154 |
2013 |
|
TNFRSF10A
|
Neoplasms
|
0.400 |
Biomarker |
BEFREE |
8p21.3 deletion suggesting a probable role of TRAIL-R1 and TRAIL-R2 as candidate tumor suppressor genes in the pathogenesis of multiple myeloma.
|
23423784 |
2013 |
|
TNFRSF10A
|
Neoplasms
|
0.400 |
AlteredExpression |
BEFREE |
Additionally, HSP70 suppression inhibited the phosphorylation of ERK, AKT, and PKC, thereby downregulating c-FLIP-L. A549 xenografts in mice receiving HSP70 siRNA showed TRAIL-induced cell death and increased DR4/DR5 levels and reduced tumor growth.
|
22948392 |
2013 |
|
TNFRSF10A
|
Neoplasms
|
0.400 |
GeneticVariation |
BEFREE |
Perturbed apoptosis due to missense alterations in candidate tumor suppressor gene Death receptor 4 (DR4) and in caspases (Casp) lead to deregulated cell proliferation and cancer predisposition.
|
21700414 |
2011 |
|
TNFRSF10A
|
Neoplasms
|
0.400 |
Biomarker |
BEFREE |
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces tumour cell apoptosis by binding to death receptor 4 (DR4) and DR5.
|
20087343 |
2010 |
|
TNFRSF10A
|
Neoplasms
|
0.400 |
AlteredExpression |
BEFREE |
In conclusion, our results in tumour samples from CRC patients suggest TRAIL-R1-mediated apoptotic depletion of infiltrating immune cells (CD8+) in response to TRAIL expression by the tumour itself.
|
20580220 |
2010 |
|
TNFRSF10A
|
Neoplasms
|
0.400 |
GeneticVariation |
BEFREE |
TNFRSF10A genotypes were not associated with tumor stage, grade, risk group or age at diagnosis.
|
18163425 |
2008 |
|
TNFRSF10A
|
Neoplasms
|
0.400 |
Biomarker |
BEFREE |
The death ligand Apo2L/TRAIL (Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand) eradicates many tumor types while sparing most normal tissues.
|
17479107 |
2007 |
|
TNFRSF10A
|
Neoplasms
|
0.400 |
GeneticVariation |
BEFREE |
In this study we analyzed the complete coding region of TNFRSF10A and TNFRSF10B in a series of 32 MCL and 101 CLL samples and detected a single nucleotide polymorphism (SNP) in TNFRSF10A (A683C) with tumor specific allele distribution.
|
16217763 |
2006 |
|
TNFRSF10A
|
Neoplasms
|
0.400 |
AlteredExpression |
BEFREE |
TRAIL-R1 and TRAIL-R2 expression on tumor cells are independent prognostic factors for survival in patients with a glioblastoma multiforme.
|
16544055 |
2006 |
|
TNFRSF10A
|
Neoplasms
|
0.400 |
GeneticVariation |
BEFREE |
Perturbed apoptosis due to missense alterations in the candidate tumor suppressor gene DR4 leads to deregulated cell proliferation and cancer predisposition.
|
17035413 |
2006 |
|
TNFRSF10A
|
Neoplasms
|
0.400 |
Biomarker |
BEFREE |
In vitro studies showed that TRAIL-induced apoptosis was dependent on TRAIL-R1 and/or -R2 dosage in most tumors.
|
16051735 |
2005 |
|
TNFRSF10A
|
Neoplasms
|
0.400 |
GeneticVariation |
BEFREE |
Thus, genetic alterations within the candidate tumour suppressor gene DR4 would be expected to provoke a deficient apoptotic signalling thereby facilitating the development of cancer.
|
15975957 |
2005 |
|
TNFRSF10A
|
Neoplasms
|
0.400 |
Biomarker |
BEFREE |
Polymorphisms of death receptor 4 (DR4) might impair the apoptotic signal transduction and lead to dysregulation of the homeostasis between cell survival and cell death, promoting tumor development and progression.
|
15863153 |
2005 |
|
TNFRSF10A
|
Neoplasms
|
0.400 |
AlteredExpression |
BEFREE |
Some HCV-related HCC cases, however, demonstrated elevated caspase-3 activity and TRAIL-R1, -R2 expression in tumor tissue.
|
12632104 |
2003 |
|
TNFRSF10A
|
Neoplasms
|
0.400 |
Biomarker |
BEFREE |
The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptors TRAIL-R1, -R2, -R3 and -R4 are located on 8p21-p22 and might be candidate tumor suppressor genes in this region.
|
12385006 |
2002 |
|
TNFRSF10A
|
Neoplasms
|
0.400 |
AlteredExpression |
BEFREE |
In addition, decreased CD31/PECAM expression and upregulation of APO2/TRAIL were observed in tumors expressing MDA-7.
|
12085234 |
2002 |
|
TNFRSF10A
|
Neoplasms
|
0.400 |
AlteredExpression |
BEFREE |
Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
|
11289151 |
2001 |
|
TNFRSF10A
|
Neoplasms
|
0.400 |
GeneticVariation |
BEFREE |
Overall, eight tumors (6.8%) were found to have two TRAIL-R1 gene mutations or six TRAIL-R2 gene mutations.
|
11313970 |
2001 |
|
TNFRSF10A
|
Neoplasms
|
0.400 |
AlteredExpression |
BEFREE |
Of the 8 tumors that were cured, Fas was expressed in 3 (38%), TRAIL-R1 in 6 (75%) and tumor necrosis factor (TNF)-R1 in 8 (100%), whereas these pro-apoptotic receptors were present in only 1 (14%), 1 (14%), and 4 (57%) of the 7 tumors that went on to recur, respectively.
|
11733907 |
2001 |